Skip to main content
. Author manuscript; available in PMC: 2017 Aug 22.
Published in final edited form as: Cancer. 2016 Sep 20;122(24):3765–3775. doi: 10.1002/cncr.30342

Figure 1.

Figure 1

Selected investigational agents and targets in metastatic pancreatic cancer. ALK, anaplastic lymphoma kinase; CCL2, chemokine (C-C motif) ligand 2; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCL1/2, chemokine (C-X-C motif) ligand 1/2 (CXCL1/2); EGFR, epidermal growth factor receptor; FAK, focal adhesion kinase; HER3, human epidermal growth factor receptor 3; mTOR, mammalian target of rapamycin; MUC5AC, mucin 5AC, oligomeric mucus/gel-forming; PARP, poly(ADP-ribose) polymerase; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PI3K, phosphoinositide 3-kinase.